Please login to the form below

Not currently logged in

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  
 FDA building

The US FDA has approved Bristol-Myers Squibb's Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Evotaz combines BMS' Reyataz (atazanavir) with Gilead Science's boosting agency cobicistat as part of a once-daily pill to be taken over a 48-week course.

The treatment is the outcome of an agreement made between BMS and Gilead in 2011, when they agreed to develop and market a fixed-dose combination HIV treatment

Murdo Gordon, head of worldwide markets at BMS, commented: “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations.”

Cobicistat is already a crucial part of several HIV treatments, including Rezolsta/Prezcobix, which pairs the drug with Janssen's Prezista (darunavir), and Gilead's own combination therapy Stribild.

Reyataz is also a successful monotherapy treatment for HIV managing worldwide revenues of more than $1bn for the first nine months of 2014.

BMS is responsible for the manufacturing and sale of the cobicistat-boosted eyataz product and will pay Gilead royalties on sales.


Article by
Kirstie Pickering

2nd February 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....